Human Oncology & Pathogenesis Program
The Gabrielle Rizzuto Lab
The Gabrielle Rizzuto lab investigates a long-standing question in immunology: what prevents maternal immune rejection of the placenta and fetus?
The immune system must be able to discriminate self from non-self. Pregnancy is a beautiful exception to the paradigm that non-self is immunogenic, since the maternal immune system does not reject the placenta and fetus. The placenta is the incredible organ that grows and invades into the maternal uterus to foster nutrient and gas exchange to the developing fetus. The maternal immune system is directly exposed to placental cells and their non-self proteins.
Our research is focused on figuring out the cellular and molecular mechanisms that underlie maternal immune tolerance of fetal and placenta proteins. Like the placenta, tumor cells also escape immune rejection despite tumor cell expression of altered-self proteins. Discovering mechanisms of fetomaternal tolerance will therefore provide a window for identifying innovative ways to make the immune system respond to tumors.
Rizzuto G, Brooks JF, Tuomivaara ST, McIntyre TI, Ma S, Rideaux J, Zikherman J, Fisher SJ, Erlebacher A. Establishment of fetomaternal tolerance through glycan-mediated B cell suppression. Nature. 2022; 603(7901): 497-502.
Hirschhorn D*, Warner AB*, Maniyar R, Chow A, Mangarin LMb, Cohen AD, Hamadene L, Rizzuto GA, Budhu S, Suek N, Liu C, Houghton AN, Merghoub T, Wolchok JD. Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI Insight. 2021; Oct 22; 6(20): e151035.
Castel P, Dharmaiah S, Sale MJ, Messing S, Rizzuto G, Cuevas-Navarro A, Cheng A, Trnka MJ, Urisman A, Esposito D, Simanshu DK, McCormick F. RAS interaction with Sin1 is dispensable for mTORC2 assembly and activity. Proc Natl Acad Sci USA. 2021 Aug 17; 118(33): e2103261118.
Gabrielle Rizzuto, MD, PhD
- The Gabrielle Rizzuto lab investigates a long-standing question in immunology: what prevents maternal immune rejection of the placenta and fetus?
- MD, Weill Cornell Medical College
- PhD, Weill Cornell Graduate School of Medical Sciences
- [email protected]
- Email Address
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Gabrielle Rizzuto discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.